Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies.
Salud Publica Mex
; 60(6): 645-652, 2018.
Article
em En
| MEDLINE
| ID: mdl-30699269
ABSTRACT
OBJECTIVE:
Describe the natural history of anal HPV among men. MATERIALS ANDMETHODS:
Prospective study among men 18-70 years (n=665), from Cuernavaca, Mexico who completed questionnaires and provided specimens (HPV genotyped) at enrollment and 1+ follow-up visit. HPV prevalence and incidence were estimated. Prevalence ratios were calculated with Poisson regression using robust variance estimation. Person-time for incident HPV infection was estimated using number of events modeled as Poisson variable for total person-months.RESULTS:
Anal infection prevalence any HPV type=15%, high-risk=8.4%, HPV16=1.4%, tetravalent vaccine types (4vHPV)=4.4%, nonavalent vaccine types (9vHPV)=6.3%. Factors associated with prevalence 50+ lifetime female sex partners (adjusted prevalence ratio, a PR=3.25, 95% CI1.12- 9.47), 10+ lifetime male sex partners (aPR=3.06, 95%CI1.4- 6.68), and 1+ recent male anal sex partners (aPR=2.28, 95%CI1.15-4.5). Anal incidence rate high-risk HPV=7.8/1000 person-months (95%CI6.0-10.1), HPV16=1.8/1000 personmonths (95%CI1.1-2.9),4vHPV=3.4/1000 person-months (95%CI2.3-4.9) and 9vHPV=5.5/1000 person-months (95%CI4.1-7.5).CONCLUSIONS:
Implementation of universal HPV vaccination programs, including men, is a public health priority.RESUMEN
OBJETIVO:
Generar evidencia que apoye la vacunación universal contra VPH. MATERIAL YMÉTODOS:
Estudio prospectivo con hombres 18-70 años (n=665) de Cuernavaca, México con cuestionarios y genotipificación de VPH en muestras (2+mediciones). Se estimó prevalencia e incidencia; se calcularon tasas de prevalencia con regresión Poisson. Se estimó persona-tiempo para infecciones incidentes.RESULTADOS:
Prevalencia de infección anal cualquier tipo de VPH=15%, altoriesgo=8.4%, VPH16=1.4%, tipos en vacuna tetravalente=4.4% y tipos en vacuna nonavalente=6.3%. Factores asociados con infección prevalente 50+ parejas sexuales femeninas en la vida (tasa de prevalencia ajustada, TPa=3.25, IC95%1.12-9.47); 10+ parejas sexuales masculinas en la vida (TPa=3.06, IC95%1.4- 6.68) y 1+ parejas masculinas (sexo anal) recientes (TPa=2.28, IC95%1.15-4.5). Tasas de incidencia para infección anal VPH alto-riesgo=7.8/1000 persona-meses (IC95%6.0-10.1), VPH 16=1.8/1000 persona-meses (95%IC1.1-2.9), tipos en vacuna tetravalente=3.4/1000 persona-meses y tipos en vacuna nonavalente=5.5/1000 persona-meses.CONCLUSIONES:
mplementación de programas de vacunación universal (incluyendo hombres) contra VPH es una prioridad en salud pública.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Incidence_studies
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Mexico
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article